Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm;Custos e eficácia da toxina botulínica tipo A no tratamento do blefaroespasmo essencial e espasmo hemifacial

Arquivos Brasileiros de Oftalmologia

Volumn 69, Issue 5, 2006, Pages 701-705

  Lasalvia, Cintia Gomes Galvão ^a,c   de Sousa Pereira, Luciano ^a   da Cunha, Marcos Carvalho ^a   Kitadai, Silvia Prado Smit ^b  

^a FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^b UNIVERSITY OF SANTO AMARO   (Brazil)

^c NONE   (Brazil)

Author keywords

Blepharospasm drug therapy; Botulinum toxin type A economics; Botulinum toxin type A therapeutic use; Costs and cost analysis; Dystonia; Hemifacial spasm durg therapy; Muscle spasticity

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; BLEPHAROSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DATA ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HEMIFACIAL SPASM; HUMAN; MALE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; QUESTIONNAIRE; RANK SUM TEST;

EID: 33751393974     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492006000500016     Document Type: Article

References (19)

1. Osaki MH, Belfort Jr R. Qualidade de vida e custos diretos em pacientes com blefaroespasmo essencial e espasmo hemifacial, tratados com toxina botulínica A. Arq Bras Oftalmol. 2004:67(1):43-9.
2. Demer JD, Holds JB, Hovis LA. Ocular movements in essential blepharospasm. Am J Ophthalmol. 1990;110(6):674-82.
3. Kennedy RH, Waller RR, Henderson JW, Kesty KR. Management of blepharospasm. Ophthal Plast Reconstr Surg. 1985;1(4):253-61.
4. Defazio G, Livrea P. Epidemiology of primary blepharospasm. Mov Disord. 2002,17(1):7-12.
5. Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain. 2002:18(6 Suppi):S142-6.
6. Kowal L, Davies R, Kiely PM. Facial muscle spasms: an Australian study. Aust N Z J Ophthalmol, 1998;26(2):123-8.
7. Lindeboom R, De Haan R, Aramideh M, Speelman JD. The blepharospasm disability scale: an instrument for the assessment of functional health in blepharospasm. Mov Disord. 1995;10(4):444-9.
8. Shorr N, Seiff SR, Kopelman J. The use of botulinum toxin in blepharospasm. Am J Ophthalmol. 1985,99(5):542-6. 19.
9. Lucci LMD. Blefaroespasmo essencial benigno. Arq Bras Oftalmol. 2002,65(5): 585-9.
10. Barbosa ER, Silva HC, Haddad MS, Bittar MS. Blefaroespasmo: tratamento com toxina botulínica. Rev Hosp Clin Fac Med S Paulo. 1996;51(6):220-3.
11. Anderson RL, Patel BC, Holds JB, Jordan DR. Related Articles, Links Blepharospasm: past, present, and future. Ophthal Plast Reconstr Surg. 1998,14(5): 305-17.
12. Cunha MC, Aguire OP, Souza-Dias CR. Tratamento do espasmo facial unilateral com toxina botulínica tipo A. Arq Bras Oftalmol. 1998;61(1):54-60.
13. Barbosa ER, Costa MDL, Staut CC, Bacheschi LA, Bittar MS. Espasmo hemifacial familiar: relato de dois casos. Arq Neuropsiquiatr. 1998;56(1):111-5.
14. Schellini SA, Matai O, Igami TZ, Padovani CR, Padovani CP. Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review. Arq Bras Oftalmol. 2006;69(1):23-6
15. a ed. São Paulo: Saraiva; 2001.
16. Siegel S, Castellan NJ Jr. Non parametric statistics. 2nd ed. New York: McGraw-Hill, 1988.
17. Andrade LA, Borges V, Ferraz HB, Azevedo-Silva SM. Experiência com aplicação de toxina botulínica A em 115 pacientes. Arq Neuropsiquiatr. 1997:55(3B):553-7.
18. Martins D. Contabilidade de custos. 4a ed. São Paulo: Atlas, 1990.
19. Martins D. Custos e orçamentos hospitalares. São Paulo: Saraiva; 2001.